A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!
Search results for
"EGFR"
-
-
Apparatus
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).